Wall Street Zen Upgrades Lantheus (NASDAQ:LNTH) to Strong-Buy

Lantheus (NASDAQ:LNTH) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a report released on Saturday.

A number of other research analysts also recently issued reports on LNTH. Truist Financial boosted their price target on Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a report on Friday, February 27th. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Citizens Jmp lifted their target price on shares of Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a report on Tuesday, February 24th. JonesTrading cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Finally, Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Tuesday, February 24th. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $82.17.

Lantheus Trading Down 4.9%

Shares of NASDAQ:LNTH opened at $72.56 on Friday. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52. Lantheus has a 52-week low of $47.25 and a 52-week high of $111.29. The stock has a market cap of $4.69 billion, a price-to-earnings ratio of 21.53 and a beta of -0.11. The business has a 50-day moving average price of $69.11 and a 200-day moving average price of $60.90.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. The firm had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.Lantheus’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts predict that Lantheus will post 6.01 EPS for the current year.

Institutional Trading of Lantheus

A number of hedge funds have recently bought and sold shares of LNTH. Vanguard Group Inc. lifted its stake in Lantheus by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after purchasing an additional 115,338 shares in the last quarter. M&T Bank Corp purchased a new stake in shares of Lantheus in the fourth quarter valued at approximately $370,950,000. Farallon Capital Management LLC increased its holdings in shares of Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after purchasing an additional 1,950,252 shares during the last quarter. Reinhart Partners LLC. increased its holdings in shares of Lantheus by 15.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock valued at $103,990,000 after purchasing an additional 214,820 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Lantheus by 3.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after buying an additional 44,374 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.